Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma

Cancer

Volumn 98, Issue 8, 2003, Pages 1569-1577

  Foulkes, William D ^a,m   Metcalfe, Kelly ^b,c   Hanna, Wedad ^c   Lynch, Henry T ^d   Ghadirian, Parviz ^e   Tung, Nadine ^f   Olopade, Olofunmilayo ^g   Weber, Barbara ^h   McLennan, Jane ⁱ   Olivotto, Ivo A ^j   Sun, Ping ^c   Chappuis, Pierre O ^a   Bégin, Louis R ^k   Brunet, Jean Sébastien ^a,l   Narod, Steven A ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j BRITISH COLUMBIA CANCER AGENCY   (Canada)

^k HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^l Algorithme Pharma Inc   (Canada)

^m MONTREAL GENERAL HOSPITAL   (Canada)

more..

Author keywords

Axillary lymph nodes; BRCA1; BRCA2; Breast carcinoma; Early diagnosis; Metastases; Survival; Tumor size

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CANCER SIZE; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FAMILIAL CANCER; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NORTH AMERICA; ONCOGENE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0141889314     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11688     Document Type: Article

References (23)

1. Fisher B, Slack NH, Bross ID. Cancer of the breast: size of neoplasm and prognosis. Cancer. 1969;24:1071-1080.
2. Smart CR, Myers MH, Gloeckler LA. Implications from SEER data on breast cancer management. Cancer. 1978;41:787-789.
3. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45:2917-2924.
4. Reger V, Beito G. Jolly PC. Factors affecting the incidence of lymph node metastases in small cancers of the breast. Am J Surg. 1989;157:501-502.
5. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.
6. Olivotto IA, Jackson JS, Mates D, et al. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer. 1998;83:948-955.
7. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1-and BRCA2-related breast cancer. Semin Surg Oncol. 2000;18:287-295.
8. Foulkes WD, Rosenblatt J, Chappuis PO. The contribution of inherited factors to the clinicopathological features and behavior of breast cancer. J Mammary Gland Biol Neoplasia. 2001;6:453-465.
9. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138-1145.
10. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171-182.
11. Foulkes WD, Wong N, Brunet JS, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res. 1997;3:2465-2469.
12. Goffin JR, Chappuis PO, Bégin LR, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer. 2003;97:527-536.
13. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539-548.
14. Van't Veer LJ, Dai HY, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
15. Lakhani SR, van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310-2318.
16. Straume O, Chappuis PO, Salvesen HB, et al. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res. 2002;62:6808-6811.
17. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33:49-54.
18. van de Vijver MJ, He YD, Van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
19. Moller P, Borg A, Evans DG, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer. 2002;101:555-559.
20. Eerola H, Vahteristo P, Sarantaus L, et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer. 2001;93:368-372.
21. Bernards R, Weinberg RA. A progression puzzle. Nature. 2002;418:823.
22. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19:924-930.
23. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997;3:222-225.